TuHURA Biosciences, Inc. (HURA)
HURA moved a median of 0.00% 30 minutes after news, and -0.25% by the close. How HURA actually reacts to news — the realized, point-in-time move the market made, measured across 154 labeled events over the last three years with zero look-ahead.
HURA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.01% | 51% | 154 |
| 30-min | 0.00% | 47% | 154 |
| 60-min | -0.13% | 46% | 154 |
| to close | -0.25% | 48% | 153 |
| Middle 50% of HURA reactions | -1.34% to +2.15% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 154 |
Half of all TuHURA Biosciences, Inc. news events land between -1.34% and +2.15% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How HURA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 16 | -0.26% | 50% | -4.66% |
| Rating reiterations | 14 | +0.68% | 50% | -2.10% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how HURA ranks against every other measured name →
That’s how HURA usually reacts — get an email when it moves on news →Email me when HURA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to HURA's baseline. Nothing else.
Recent HURA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K TuHURA Biosciences, Inc. For: Oct 09 | SEC filing · Form 8-K | SEC EDGAR | +0.57% | +1.71% | |
| TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 | Press release | PR Newswire | +0.00% | -5.24% | |
| TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology | Press release | PR Newswire | -0.98% | -3.61% | |
| Form 8-K TuHURA Biosciences, Inc. For: Sep 21 | SEC filing · Form 8-K | SEC EDGAR | -3.28% | -1.87% | |
| Form 8-K TuHURA Biosciences, Inc. For: Sep 14 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | -0.47% | |
| Form 8-K/A TuHURA Biosciences, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | +1.95% | |
| Form 8-K TuHURA Biosciences, Inc. For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.49% | +1.95% | |
| TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers | Press release | PR Newswire | +0.54% | +0.00% | |
| TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | -0.88% | -1.40% | |
| Form 8-K TuHURA Biosciences, Inc. For: Sep 02 | SEC filing · Form 8-K | SEC EDGAR | -0.88% | -1.40% | |
| Form 8-K TuHURA Biosciences, Inc. For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | -3.33% | +2.38% | |
| Form 8-K TuHURA Biosciences, Inc. For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | +2.21% | -1.77% | |
| Form 10-Q TuHURA Biosciences, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.75% | +7.86% | |
| Form 8-K TuHURA Biosciences, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | +7.86% | |
| TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | Press release | PR Newswire | -1.75% | +7.86% | |
| Form 8-K TuHURA Biosciences, Inc. For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -1.75% | +7.86% | |
| Form 8-K TuHURA Biosciences, Inc. For: Jul 28 | SEC filing · Form 8-K | SEC EDGAR | -0.95% | +2.84% | |
| TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference | Press release | PR Newswire | -1.34% | +0.00% | |
| Form ARS TuHURA Biosciences, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +2.15% | +2.58% | |
| Form DEF 14A TuHURA Biosciences, Inc. For: Aug 18 | SEC filing · Form DEF | SEC EDGAR | +2.15% | +2.58% | |
| Form DEFA14A TuHURA Biosciences, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +2.15% | +2.58% | |
| Form 8-K TuHURA Biosciences, Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | -0.45% | +2.70% | |
| Form PRE 14A TuHURA Biosciences, Inc. For: Aug 18 | SEC filing · Form PRE | SEC EDGAR | -1.59% | +4.09% | |
| Form 8-K TuHURA Biosciences, Inc. For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +2.19% | +12.72% | |
| TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers | Press release | PR Newswire | -1.24% | -6.20% | |
| Form 8-K TuHURA Biosciences, Inc. For: May 26 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | +0.45% | |
| Form 10-Q TuHURA Biosciences, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.76% | +12.83% | |
| Form 8-K TuHURA Biosciences, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +1.76% | +12.83% | |
| TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | PR Newswire | +1.76% | +12.83% | |
| TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference | Press release | PR Newswire | +0.00% | +0.83% | |
| Form 10-K/A TuHURA Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | +1.75% | |
| Form 8-K/A TuHURA Biosciences, Inc. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.75% | |
| Form 8-K TuHURA Biosciences, Inc. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | +0.90% | -3.60% | |
| TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028 | Press release | PR Newswire | +0.90% | -3.60% | |
| Form 8-K TuHURA Biosciences, Inc. For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -1.66% | +8.29% | |
| TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations | Press release | PR Newswire | +0.00% | +7.27% | |
| Form 8-K TuHURA Biosciences, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | -1.36% | -11.96% | |
| TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | Press release | PR Newswire | -1.36% | -11.96% | |
| Form 10-K TuHURA Biosciences, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.36% | -11.96% | |
| Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers | Press release | PR Newswire | -1.80% | +2.06% | |
| TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement | Press release | PR Newswire | -0.65% | +7.74% | |
| TuHURA Biosciences Announces Participation in Upcoming Investor Conferences | Press release | PR Newswire | -3.95% | +16.67% | |
| TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers | Press release | PR Newswire | -4.43% | -18.12% | |
| TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | Press release | PR Newswire | -0.67% | +6.11% | |
| TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma | Press release | PR Newswire | +2.15% | -7.34% | |
| Form 8-K TuHURA Biosciences, Inc. For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +2.15% | -7.34% | |
| TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone | Press release | PR Newswire | +0.00% | -5.55% | |
| TuHURA Biosciences Provides Corporate Update Following Recent Financing | Press release | PR Newswire | +2.43% | +0.48% | |
| Form 8-K TuHURA Biosciences, Inc. For: Dec 09 | SEC filing · Form 8-K | SEC EDGAR | +2.43% | +0.48% | |
| TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering | Press release | PR Newswire | -11.56% | -32.37% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the HURA section they belong to.
Where else HURA is measured.
HURA earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is TuHURA Biosciences, Inc.'s median reaction calculated?
Every labeled HURA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 154 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of HURA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does HURA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.